



JSC Servier enters into Agreement with Minerva Pharmaceutical (Galenica Group) for Proctosynalar cream and suppositories (INN: Fluocinolone Acetonide + Lidocaine) in prevention and treatment of haemorrhoids

Moscow, October 20, 2017 – JSC “**Servier**” is pleased to announce the signing of a strategic agreement with Minerva Pharmaceutical. Under this agreement, Minerva grants Servier the exclusive rights for Proctosynalar cream and suppositories in Russia and Eurasian Economic Union, and Servier will become the Marketing Authorization Holder.

Proctosynalar is a multicomponent original combination in rectal and topical forms discovered by Minerva. Product is indicated for the prevention and for the treatment of internal and external haemorrhoids, proctitis, perianal eczema, anal fissures, anal itching.

Proctosynalar is not registered in Russia, nowadays product is available in Greece in OTC status. Launch in Russia is expected in 2020 in OTC status.

This partnership is a great opportunity for Servier to increase market share in haemorrhoids segment with a product of unique composition.

About Servier Group

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth.

Servier is a key player also in phlebology and haemorrhoids, one of its main therapeutic areas. Its portfolio of innovative treatments is being developed with partners worldwide.

For more information visit www.servier.com

About Servier Russia

Servier has been active in Russia for 25 years, where it is one of the leading pharmaceutical companies. In 1999, the company established its Russian Center for Therapeutic Research in Moscow. In 2007, a high-tech pharmaceutical plant opened in Russia in full compliance with GMP standards. Today it is a full-scale plant producing original medicines intended for treatment of major non-communicable diseases for Russian citizens. In 2012 Servier became one of the first international companies to start exporting its products produced in Russia to the CIS countries.

For more information visit www.servier.ru

About Minerva Pharmaceutical

Minerva Pharmaceutical (Minerva) is one of the main drug producers in Greece, it has been established in 1933, based in Athens and belongs to the Galenica Group.

The structure of manufacturing program is focused on medicines that belong to mass therapeutic use. It offers non steroid anti-inflammatory drugs, drugs for the treatment of peptic ulcers, dermatological products, antidepressants, anticonvulsants – antiepileptics, drugs for manic-depressive illness, metabolites of fatty acids, anabolic steroids, nasal decongestants, vitamins, antihemorrhoidal and antihypertensive drugs, calcium regulating and antibacterial agents, lipid regulating and antitussive agents, anti-allergic drugs, aural, and anti-diabetic drugs.

Minerva Pharmaceutical engages in the manufacture, marketing, promotion, and distribution of pharmaceutical products in Greece and internationally.

For more information visit www.minervapharm.gr